SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Regeneron Reports 37% Lower Risk of Death in Longer-Term Libtayo Trial Data

Regeneron reported nearly four-year follow-up from the Phase III C-POST trial, showing a 37% reduction in risk of death with Libtayo in CSCC.

REGN

Related stories